Diverse product pipelines

2021-05-26 17:43:58 浙江昂大久力生物制药有限公司 Viewd 348

The pipeline products include E2HSA and other approved type 2 diabetes treatment combination drugs, weight management drugs, interleukin-2 fusion protein tumor treatment adjuvant drugs.


ProductUsePreclinical research, clinical phase I, clinical phase II, clinical phase III

Estimated completion date for the current phase

E2HSAType 2 diabetes injection, GLP-1 weekly preparation, minimal hypoglycemiaDecember 2021
E2HSA+MetforminTo treat type 2 diabetes, in combination with metforminDecember 2024
Interleukin-2 fusion proteinAdjuvant drugs for cancer treatmentSecond half of 2022